Arcellx (ACLX) – Analysts’ Recent Ratings Updates

Several brokerages have updated their recommendations and price targets on shares of Arcellx (NASDAQ: ACLX) in the last few weeks:

• 1/7/2026 – Arcellx is now covered by analysts at UBS Group AG. They set a “buy” rating on the stock.
• 1/7/2026 – Arcellx is now covered by analysts at UBS Group AG. They set a “buy” rating and a $100.00 price target on the stock.
• 12/22/2025 – Arcellx is now covered by analysts at Wells Fargo & Company. They set an “overweight” rating and a $100.00 price target on the stock.
• 12/22/2025 – Arcellx is now covered by analysts at Wells Fargo & Company. They set an “overweight” rating and a $100.00 price target on the stock.
• 12/8/2025 – Arcellx had its “buy” rating reaffirmed by analysts at Canaccord Genuity Group Inc.. They now have a $130.00 price target on the stock.
• 12/8/2025 – Arcellx had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $105.00 price target on the stock.
• 11/24/2025 – Arcellx had its “buy” rating reaffirmed by analysts at Citigroup Inc..
• 11/24/2025 – Arcellx had its “buy” rating reaffirmed by analysts at Guggenheim.
• 11/18/2025 – Arcellx is now covered by analysts at Wolfe Research. They set a “peer perform” rating on the stock.

Insider Buying and Selling

In other news, insider Christopher Heery sold 340 shares of the firm’s stock in a transaction dated Monday, November 17th. The stock was sold at an average price of $90.00, for a total value of $30,600.00. Following the sale, the insider directly owned 284 shares of the company’s stock, valued at approximately $25,560. This trade represents a 54.49% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 8.35% of the company’s stock.

Arcellx, Inc (NASDAQ: ACLX) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation cell therapies for oncology and autoimmune diseases. The company’s proprietary ARC-SparX™ platform is designed to enable precise control over cell-surface receptor activation and to improve the safety, efficacy and durability of adoptive cell therapies. Leveraging this technology, Arcellx engineers immune cells with modular antigen-binding domains that can be exchanged to target a variety of disease-associated markers.

The company’s pipeline comprises multiple wholly owned programs in hematologic malignancies and solid tumors at various stages of preclinical and clinical development.